Rein Therapeutics (RNTX) investor relations material

Background and pipeline

• Focus on pulmonary orphan diseases, with two Phase II-ready respiratory programs and idiopathic pulmonary fibrosis (IPF) the priority.

• Began as Lung Therapeutics, a private Austin-based company; reverse merger with Aileron Therapeutics closed in Oct 2023, followed by a Rein rebrand in early 2025.

LTI-03 mechanism and delivery

• LTI-03 supplies a portion of caveolin-1’s scaffolding domain to restore regulatory activity that is missing in fibrosis; the approach may affect multiple fibrosis pathways and lung cell types.

• An off-the-shelf dry powder inhaler aims for local lung coverage with limited systemic uptake; Phase I-B experience supported adequate inspiratory capacity in IPF patients.

• Dosing in RENEW is 2.5 mg or 5 mg twice daily; the high-resistance inhaler is designed for patients with low inspiratory capacity and delivers the dose in one or two inhalations.

RENEW trial and milestones

• Global, 24-week Phase II IPF study assesses HRCT and forced vital capacity; enrollment was reported 25% faster than expected, with sites in the U.S., U.K., Australia, Germany, Poland, Bulgaria and Romania.

• Eligibility requires confirmed IPF and sufficient lung capacity for disease progression; approved background therapies are allowed, with treatment groups stratified by background therapy.

• A blinded 12-week snapshot covering safety, tolerability and lung-function data from a subset of 20–40 patients is planned before year-end 2026; it will not unblind the trial or guide decisions.

• Last patient enrollment is expected around spring 2027; trial data are expected before year-end 2027.